0.02
+25.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cynata Therapeutics
Its shares trade on ASX under the ticker CYP.AX. It has been listed since 20 December 2007. In the fiscal year to 30 June 2026, it reported revenue of A$1.7m and a net loss of A$9.1m. At that date it held total assets of A$1.4m and shareholders' equity of −A$394,240.
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-12-20. The firm is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, Cymerus. Its Cymerus technology facilitates manufacture of MSCs from a single donor and a single donation. The firm's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). The firm's technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an off-the-shelf stem cell platform for therapeutic product use. The firm's MSCs produced using Cymerus technology, can be used to treat unrelated patients, without any need to match the recipient to the donor.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Dec 2007
- Website
- cynata.com ↗
Leadership
Pay as last reported
- Dr. Geoffrey BrookeIndependent Non-Executive Chairman of the BoardA$461,379
- Dr. Kilian KellyChief Executive Officer, Managing Director, Director, since 2019A$499,381
- Dr. Suzanne LipeVice President - Partner EngagementA$233,395
- Dr. Jolanta AireyChief Medical OfficerA$348,712
- Mr. Peter WebseCompany Secretary, since 2009A$43,855
- Ms. Janine RolfeDirector
- Dr. Darryl MaherNon-Executive Independent DirectorA$107,707
- Dr. Paul WottonNon-Executive Independent DirectorA$107,707
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cynata Therapeutics Ltd possesses a portfolio of patented technology, providing a competitive advantage in the regenerative medicine industry. This intellectual property positions the company well for future growth and may lead to potential licensing opportunities.
- The company has established efficient and scalable manufacturing capabilities for its innovative stem cell products. This ensures consistent product quality, timely delivery, and cost-effectiveness, enabling Cynata to meet the growing demand for regenerative therapies.
Weaknesses
- Despite advancing its proprietary Cymerus™ technology, Cynata Therapeutics currently has a limited product pipeline. Relying heavily on the success of their lead product, CYP-001, poses risks in case of regulatory challenges or market dynamics.
- Cynata heavily relies on strategic collaborations and partnerships to fund research and development activities. While collaborations bring resources and expertise, any disruptions or termination of these partnerships could significantly impact the company's financial stability and ability to execute its business plans.
Opportunities
- The regenerative medicine market is experiencing rapid growth worldwide, creating abundant opportunities for Cynata Therapeutics to expand its market reach. By capitalizing on their patented technology and diversified portfolio, the company can target multiple therapeutic areas and geographies.
- Advancements in stem cell research are constantly revealing new therapeutic applications. Cynata can leverage its technological expertise and collaborate with academic institutions or other industry players to explore and develop innovative treatments for various diseases and medical conditions.
Threats
- The regenerative medicine industry is highly competitive, with numerous companies vying for market share and intellectual property rights. Cynata faces the risk of competition from established biotechnology companies and emerging startups, which could impede its market penetration and revenue growth.
- The development and commercialization of regenerative medicine products are subject to stringent regulatory requirements. Changes in regulations or delays in obtaining necessary approvals from regulatory authorities can significantly hinder Cynata's product launches and expansion plans.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.